FrontierWhat is becoming possible?
The BCI Frontier
A map of what brain-computer interfaces can do, arranged by how firmly each capability is established: demonstrated in people at the centre, emerging possibilities at the rim. Choose a domain to see what is possible today, the latest milestone, who is working on it and what has to happen next.
- Demonstrated today
- Early clinical
- Research frontier
- Emerging possibility
Zones are qualitative editorial judgements. A capability sits in a zone, not at a point, and the map implies no ranking between domains.
Frontier domain
Closed-loop Neuromodulation
What is possible today
Responsive stimulation for epilepsy and adaptive deep brain stimulation are authorised therapies. Newer closed-loop implants for stroke recovery and depression have entered first human studies.
Latest important milestone18 Sep 2026
CorTec's Brain Interchange received a second FDA Breakthrough Device designation; three stroke participants are implanted.
Capabilities by zone
- Responsive and adaptive stimulation for specific conditionsDemonstrated today
- Closed-loop cortical stimulation for stroke recoveryEarly clinical
- Miniature stimulators for depressionEarly clinical
- Brain-controlled spinal stimulationEarly clinical
- Biomarker-driven therapy for mood disordersResearch frontier
- Network-level therapy personalised in real timeEmerging possibility
- Approaches
- Surface-electrode closed-loop implants · Epidural stimulators powered wirelessly · Graphene electrode arrays
- Clinical maturity
- Mixed: authorised devices for some indications, first-in-human studies for others.
- Labs
- University of WashingtonEPFL / Lausanne University HospitalEmory University
- Tools
- MNE-Pythonezmsg
- Patent themes
- 382 patent families concern closed loop. Filing shows where protection is sought, not that a capability works. The patent landscape
What needs to happen next
- 01Controlled evidence that closed-loop stimulation improves recovery after stroke
- 02Reliable biomarkers for psychiatric indications
- 03Long-term safety of chronic cortical stimulation
Therapeutic closed-loop systems address far larger patient populations than paralysis. If early studies hold up, this is likely where implanted neural interfaces reach the most people first.
Unresolved and emerging
Open Frontiers
The questions that decide what happens next. Each is read across six dimensions, so that scientific momentum, clinical need and capital can be seen side by side.
Open question
Scientific momentum
Clinical need
Human evidence
Technical maturity
Competition density
Capital intensity
- Early human evidence
- High technical uncertainty
Published human data extend to years for a few participants and designs. Each new electrode technology has to earn its own record.
Start fromPlug-and-play control of a brain–computer interface through neural map stabilizationSampling representational plasticity of simple imagined movements across days enables long-term neuroprosthetic controlIntracortical
- Scientific momentum
- moderate
- Clinical need
- high
- Human evidence
- moderate
- Technical maturity
- low
- Competition density
- moderate
- Capital intensity
- high
Bars show low, moderate or high on each dimension. These are BCI Briefing judgements intended to make the landscape legible. They do not rank opportunities and are not investment advice.
The outlook
What happens next?
Four horizons, from now to beyond five years. Observed trajectories are on the left; plausible milestones, necessary breakthroughs and key uncertainties follow to the right.
Now
Observed trajectory
Speech BCI word accuracy over large vocabularies rose from about 76% to 97.5% in peer-reviewed reports between 2023 and 2024.
A high-performance speech neuroprosthesisAn Accurate and Rapidly Calibrating Speech Neuroprosthesis
Observed trajectory
Commercial implanted BCIs are in registered feasibility studies in five countries.
Observed trajectory
Six rounds of $200M or more appear in our sample of announcements since mid-2025.
Key uncertainty
Most company performance figures have not been independently measured or peer reviewed.
1–2 years
Plausible next milestone
A pivotal trial of a permanently implanted BCI is registered.
Plausible next milestone
Peer-reviewed results appear from commercial early feasibility studies.
Necessary breakthrough
High-performance decoders that stay calibrated for months without supervised retraining.
Key uncertainty
Whether signal quality from newer electrode designs holds beyond the first years in people.
3–5 years
Plausible next milestone
A first marketing authorisation for an implanted communication or control BCI in a major market.
Necessary breakthrough
Fully implanted, wireless, high-channel systems with multi-year reliability data.
Key uncertainty
Reimbursement, surgical capacity and long-term device support — the factors that decided the pace of cochlear implant adoption.
Beyond
Plausible next milestone
Bidirectional systems that combine movement and touch in everyday use.
Necessary breakthrough
A non-implanted signal with bandwidth approaching implanted systems. There is no human evidence for this yet.
Key uncertainty
How society chooses to govern interfaces for people without a medical need.
Only the first column describes what has happened. Everything to its right is a forward-looking judgement by The BCI Briefing as of 3 Oct 2026, and should be read as uncertain.